ReviewBreast cancer research and treatment2019

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Raquel N Rozner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.